Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Recursion Pharmaceuticals Inc (RXRX) vs Viking Holdings Ltd Ordinary Shares (VIK) Price & Performance

Recursion Pharmaceuticals IncTrade
Viking Holdings Ltd Ordinary SharesTrade

Price performance (Past 24H)

Key statistics

Recursion Pharmaceuticals Inc vs Viking Holdings Ltd Ordinary Shares — how do they compare? Recursion Pharmaceuticals Inc trades at $3.98 (market cap $2.31B), while Viking Holdings Ltd Ordinary Shares trades at $81.62 (market cap $36.29B). The key difference: Viking Holdings Ltd Ordinary Shares is far larger — about 15.7× Recursion Pharmaceuticals Inc's market cap, and Viking Holdings Ltd Ordinary Shares is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Viking Holdings Ltd Ordinary Shares for 0 Days on average.

RXRXVIK
Market Cap
$2.31B$36.29B
Volume
40,478,7682,522,956
Sector
HealthConsumer Cyclical
52-Week High
$6.79$108.26
52-Week Low
$2.84$57.08
Typical Hold Time
22 Days0 Days
Enterprise Value
$1.83B$38.67B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Recursion Pharmaceuticals Inc

RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.

The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.

Viking Holdings Ltd Ordinary Shares

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

RXRX
8% Buy92% Sell
Avg holding period · 22 Days
VIK
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX →

About Viking Holdings Ltd Ordinary Shares

Viking operates river, ocean, and expedition cruises. Its itineraries focus on destination-based travel across Europe, the Americas, and other regions.

Read more on VIK →